Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Vitrakvi logo

VITRAKVI Prescribing Information

VITRAKVI has been authorised under a conditional approval scheme.

Webinars
and Events

Webinars
and Events

ASCO 2022: NTRK gene fusion tumours and the role of VITRAKVI (larotrectinib)

Description

 

This short film features Dr Alastair Greystoke, Honorary Medical Oncologist at Newcastle’s Northern Centre for Cancer Care and a lecturer in Medical Oncology at Newcastle University, discussing the latest results from ASCO 2022 as part of the TRK record series, which aims to encourage positive conversations in oncology.

 

It includes:

  • An overview of TRK fusion cancer and Dr Alastair's personal experience using VITRAKVI in his patients.
  • A detailed breakdown of the data from ASCO 2022, supporting the use of VITRAKVI, including overall response rates and median time to response.
  • Expert insight into why testing for NTRK gene fusion early is a vitally important step in the treatment of these cancers.

 

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.1
British Sarcoma Group Annual Conference 2022

British Sarcoma Group Annual Conference 2022

Be informed of future content relevant to you

Be informed of future content relevant to you

Opt-in to Bayer communications

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.

OPT-IN TO BAYER COMMUNICATIONS OPT-IN TO BAYER COMMUNICATIONS
REFERENCES

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.

 

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.